Featured Research

from universities, journals, and other organizations

Most Neuropsychological Tests Don't Tell Alzheimer's Disease From Vascular Dementia, Study Finds

Date:
July 11, 2009
Source:
American Psychological Association
Summary:
Most of the cognitive tests that have been used to decide whether someone has Alzheimer's disease or vascular dementia have not been very helpful when used alone. A new report concluded that when older people are confused and forgetful, doctors should base their diagnoses on many different types of information, including medical history and brain imaging.

Most of the cognitive tests that have been used to decide whether someone has Alzheimer's disease or vascular dementia have not been very helpful when used alone. A new report published by the American Psychological Association concluded that when older people are confused and forgetful, doctors should base their diagnoses on many different types of information, including medical history and brain imaging.

Both Alzheimer's disease and vascular dementia affect learning and memory, behavior and day-to-day function. Even so, they're caused by different problems in the brain and require different medical approaches. It's important to tell them apart accurately, stresses the study in July's Neuropsychology. Valid diagnoses can help doctors treat patients more effectively, and help patients and families better understand their situations.

Jane Mathias, PhD, and Jennifer Burke, M.Psych.(Clinical), both from the University of Adelaide, analyzed 81 previously published studies that compared the cognitive testing of people diagnosed with dementia of the Alzheimer's (4,867) and vascular type (2,263). The average age across participants was 75.

Of the 118 different tests that were used in more than one study, Mathias and Burke found that only two were able to adequately differentiate between Alzheimer's and vascular dementia.

The Emotional Recognition Task (the ability to identify facial expressions in photographs and match emotional expressions to situations, at which people with Alzheimer's were better) and Delayed Story Recall (at which people with vascular dementia were better), were the only tests that appeared to reliably tell the two groups apart.

Even so, whether due to individual variability (people start at different baselines) or possible undiagnosed mixtures of Alzheimer's and vascular disease, there was enough overlap between the two groups to signal the need for more information. Because of these muddied waters, "The combined picture is what's important, so we need to look at how we can improve diagnosis by combining different measures," said Mathias.

Of note, many commonly used tests -- such as Digit Span (repeating a set of numbers forward, backward), verbal fluency (generating words by first letter or category, such as animals), drawing tasks and more – were unable to distinguish between dementia types. "While these tests may assist in diagnosing dementia, they do not adequately discriminate between Alzheimer's disease and vascular dementia," wrote the authors. Teasing apart different types of dementia is often harder than deciding whether someone is showing cognitive decline in the first place, Mathias explained.

Although the two tests that worked best would most reliably contribute to a clinical diagnosis, "All cognitive tests should be used cautiously and only in conjunction with other information (imaging, medical history) when diagnosing patients," the authors said.


Story Source:

The above story is based on materials provided by American Psychological Association. Note: Materials may be edited for content and length.


Journal Reference:

  1. J. L. Mathias, J. Burke. Cognitive Functioning in Alzheimer's and Vascular Dementia: A Meta-Analysis. Neuropsychology, 2009; Vol. 23, No. 4.

Cite This Page:

American Psychological Association. "Most Neuropsychological Tests Don't Tell Alzheimer's Disease From Vascular Dementia, Study Finds." ScienceDaily. ScienceDaily, 11 July 2009. <www.sciencedaily.com/releases/2009/07/090708132822.htm>.
American Psychological Association. (2009, July 11). Most Neuropsychological Tests Don't Tell Alzheimer's Disease From Vascular Dementia, Study Finds. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2009/07/090708132822.htm
American Psychological Association. "Most Neuropsychological Tests Don't Tell Alzheimer's Disease From Vascular Dementia, Study Finds." ScienceDaily. www.sciencedaily.com/releases/2009/07/090708132822.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins